



PRESS RELEASE

CNS drug targeting technology 2B-Trans™ to be part of Dutch Technology Foundation grant at Leiden University

Leiden, The Netherlands - December 8, 2005 - The Dutch biotechnology company to-BBB announced today that its central nervous system (CNS) drug targeting technology, 2B-Trans™, will be part of a Dutch Technology Foundation STW grant project at Leiden University. This grant will support the preclinical project “Neuroprotective Growth Factor Delivery in Stroke” conducted by the Blood-Brain Barrier Research Group headed by Dr A.G. de Boer from the Leiden/Amsterdam Center for Drug Research (LACDR) at Leiden University. The €450,000 project will commence in January 2006 and is planned for three years.

About the 2B-Trans™ technology in acute stroke

Treatment of patients suffering from an acute stroke with neuroprotective growth factors is severely hindered due to the presence of the blood-brain barrier. Such therapeutics need to be applied to the brain within the first few hours after the stroke, and at that time the neuroprotective blood-brain barrier is still intact. to-BBB developed the unique CNS drug targeting solution 2B-Trans™ that delivers conjugated drugs into the CNS after an intravenous injection, without disruption of the blood-brain barrier. The proprietary 2B-Trans™ technology uses a well characterized and effective transport system with a specific carrier protein that has an excellent proven safety profile in humans.



About to-BBB technologies BV

to-BBB, founded in 2003, is a spin-off company from LACDR's renowned Blood-Brain Barrier Research Group at Leiden University in The Netherlands. to-BBB is located at the Bio-Science Park in Leiden.

to-BBB has recently announced a collaboration agreement with Biogen Idec and an evaluation and licence option agreement with Genmab and has signed a research agreement with another undisclosed US based top 5 biotech company. to-BBB is currently negotiating agreements with several other companies, who will be offered access to the 2B-Trans™ technology. For additional information about the company, please visit www.toBBB.com.

For further information please contact:

Alfred N. Nijkerk, PharmD, CBO

Tel: +31 6 55128387

Fax: +31 84 8709728

E-mail: Nijkerk@toBBB.com

Website: www.toBBB.com